PROJECT TEAMS
Current Projects
CereCe
Project CereCe aims to empower self-directed mobility for tetraplegic individuals by leveraging gaze-tracking and brain-computer interface (BCI) technology. The team is currently developing a retrofittable wheelchair that integrates electroencephalography (EEG) and a mounted camera to interpret users' neurological signals and guide the wheelchair's movement.
​
Comprising students and graduates from diverse fields—including medicine, engineering, computer science, data science, arts, law, and commerce—Project CereCe brings a multidisciplinary approach to innovation. The team is actively engaging with conferences, researchers and accelerators to advance their groundbreaking work.
Melbourne Bionics
The Melbourne Bionics Company builds smart wearables that help people move better and recover faster, starting with athletes. Our first product is a lower‑leg sleeve that captures rich movement signals in real training and match‑like conditions, giving teams a way to spot non‑contact injury risk earlier and act before a player goes down.
The idea began in 2022 as Project Mobi, a biodesign effort focused on active compression and recovery that earned the Graeme Clark Institute Prize. It has since evolved into a company with a clear advantage: a product athletes genuinely want to wear because it delivers immediate value. That constant use creates a proprietary stream of real‑world human motion data, which also powers a second product—a benchmarking platform that lets humanoid robotics teams test their policies against high‑performance human movement and build more robust systems without sharing raw datasets.
This helps close the gap between polished demos and real‑world deployment, where conditions are unpredictable and reliability must be extremely high.
Sensure
Project Sensure began as a volunteer-driven initiative born out of the Biodesign Innovation program, and has since evolved into a company focused on commercialising a MedTech device for lumbar puncture training. While the company advances product development and market entry, the student-volunteer team drives long-term project growth, innovation, and hands-on learning. Together, the team is developing a training tool that enhances procedural skill acquisition through real-time sensory feedback.
​In 2026, the team is co-creating a platform that integrates their product into an existing educational system, helping bring impactful technology into clinical education. We look forward to continuing to build and grow within the MedTech innovation community.
Chyral
Chyral is developing an AI-powered photonics platform to enable non-invasive, real-time measurement of human biology. Its core approach is to build a digital twin of how light interacts with living tissue, creating the foundation for biosensing applications such as non-invasive glucose monitoring and, over time, broader biomarker detection. By combining physics-based modelling, optical sensing, and AI, Chyral aims to unlock a new generation of continuous, non-destructive health monitoring technologies.
Recent achievements include completing MAP Velocity, raising angel investment for an initial proof-of-concept study, winning first place at Blackbird Foundry, being selected to present at the StartEd@Melbourne Showcase, and presenting photonics research at a major international photonics conference in San Francisco. In 2026, Chyral is focused on advancing the technical foundations of its bio-optical platform, refining prototype systems, and generating the experimental evidence needed to validate its approach.
Celiva
Project Celiva is developing a saliva-based rapid antigen test to screen for celiac disease (CeD) and gluten insensitivity based on anti-gluten and oral microbiome anti-bacterial antibodies. Our test can exponentially reduce pain, cost and time associated with both CeD diagnosis and treatment.
Celiva originated in the Summer25 Cohort of the Startmate Student Fellowship, where a 2nd place pitch gave access to a free position in their Launch Club pre-accelerator. Celiva continued to make strong progress throughout 2025, partipating in MedTech Actuator and incorporating as a company. In 2026, Celiva is focused on conducting a pilot study to validate their research.​